BioMed Updates: ELTP.OB, SOMX, STEM, GERN, ASTM, VRTX, CYTR, IMUC.OB, JAV Print E-mail
Wednesday, 02 December 2009 18:55

Below is a summary of BioMed updates from 2-Dec, summarized in 140 characters or less each.

 

$ELTP.OB / Elite Pharma soars 40% on FDA generic approval opiate pain drug methadone along with ThePharmaNetwork

$JAV / Javelin Pharma files NDA for FDA approval of Dyloject (diclofenac injection) (already approved in Europe)

$SOMX / Somaxon Pharma Awaits FDA Decision (expected 4-Dec) for insomnia drug Silenor (doxepin)

$STEM $GERN $ASTM / HavRx Global Stem Cell Index Up on New Tax-Paid Cell Lines / http://bit.ly/4J83Wi

$VRTX / Vertex Pharma Announces Proposed Public Offering AH, Down 2.5% / 10M shares stock / 1.5M options

New Report on Protox by Dundee Securites Ahead of Key Results (TSX: PRX.TO) (OTC: PTXRF.PK) / http://hub.tm/?kGFaK

$CYTR / CytRx / FDA Lifts Clinical Hold / Will resume clinial trial for arimoclomol in ALS patients

$IMUC.OB / ImmunoCellular Notches Deal with MD Anderson for New Cancer Stem Cell Vaccine Target / http://hub.tm/QOmte

Click here to follow me on twitter / mikehavrilla and check out the BioMedReports.com FDA Calendar service, which includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter resubmissions to the FDA; and (4) pending clinical trial results.

Disclosure:  Long IMUC.OB, PTXRF.PK




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter